Not yet recruitingPhase 2NCT06598384

VA as Maintenance Therapy Post Allo-HSCT in MDS and AML

Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Navy General Hospital, Beijing
Principal Investigator
Liren Qian
Navy General Hospital, Beijing
Intervention
Venetoclax combined with Azacytidine(drug)
Enrollment
40 enrolled
Eligibility
16 years · All sexes
Timeline
20242030

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06598384 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

← Back to all trials